Original Research
Accepted on 21 Nov 2024
DL-ICE as a Bridge to Allogeneic Transplantation in Relapsed/Refractory PTCL: Survival Outcomes and Prognostic Factors
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1461268
Type at least 3 characters
1,744 articles
Articles
Original Research
Published on 21 Nov 2024
Hematopoietic stem cell transplantation to improve prognosis in aggressive monomorphic epitheliotropic intestinal T-cell lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1388623
- 208 views
Original Research
Published on 21 Nov 2024
The characteristics of patients with multiple myeloma surviving over 10 years
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1490630
- 179 views
Case Report
Accepted on 20 Nov 2024
Severe atypical skin disease in two patients with CLL/SLL after BTKi treatment -A case report and literature review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1467891
Editorial
Accepted on 20 Nov 2024
Editorial: Transplantation and cellular therapy in lymphomas and plasma cell disorders.
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1527836
Systematic Review
Published on 20 Nov 2024
Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1455378
- 267 views
Original Research
Accepted on 19 Nov 2024
Exploration of risk factors and characteristics of COVID-19 infection among patients with hematological malignancies in Suzhou, China : A retrospective study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1487516
Case Report
Accepted on 18 Nov 2024
Preoperative Diagnosis of Primary Ovarian Lymphoma: a case report and a decade of insights
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1471654
Original Research
Accepted on 15 Nov 2024
Efficacy and safety of Hypomethylating Agents in the treatment of AML/MDS patients relapsed post allogenetic hematopoietic stem cell transplantation
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1465334
Case Report
Accepted on 15 Nov 2024
Clonally unrelated HL-type RS manifested as hemophagocytic syndrome: a case report and literature review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1472560
Case Report
Published on 14 Nov 2024
Hemangiopericytoma following allogeneic hematopoietic stem cell transplantation in a patient with primary plasma cell leukemia: the first case report and literature review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1467237
- 166 views
Case Report
Accepted on 11 Nov 2024
Case Report: CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B related cirrhosis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1491100
Review
Accepted on 11 Nov 2024
Updates in Novel Immunotherapeutic Strategies for Relapsed/Refractory AML
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1374963
Case Report
Accepted on 11 Nov 2024
Sustained Yet Non-Curative Response to Lenalidomide in Relapsed Angioimmunoblastic T-Cell Lymphoma with Acquired Chidamide Resistance: A Case Report with 10-Year Follow-Up, Genetic Insights and Literature Review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1471090
Case Report
Accepted on 08 Nov 2024
Castleman disease variant of POEMS syndrome without M protein: a case report
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1449945
Case Report
Accepted on 06 Nov 2024
Case Report: Successful Use of Ruxolitinib to Treat Interstitial Pneumonia as an Unusual Primary Presentation in Primary Myelofibrosis-Two Birds with One Stone
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1475036
- 125 views